Optimization of experimental assay design is crucial for the overall success of any drug discovery initiative. The factors that need to be considered include: selection of the most appropriate assay ...

FREMONT, Calif., Feb. 24, 2025 /PRNewswire/ -- Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, is proud to announce the release of the ...

Assays need to be specific for their research purpose, be that quantifying cellular levels of specific proteins, identification of potential new drug molecules, or quantitative measurements of levels ...

The mRNA Assay Development Summit is the first and only meeting to address the specific technical challenges of analytical, bioanalytical and potency assay development. This meeting will showcase ...

Bringing together technical case studies with actionable insights, the 2nd TPD Assay Development & Screening Summit returns as the only industry-dedicated conference to support in-house assay ...

A good bioassay, like a good marriage, joins two partners in a bond and is mutually beneficial. In the case of bioassays, optimal design and development and accurate statistical analysis comprise a ...

In writing about what attributes and skills qualify a scientist for a successful career in assay development for drug discovery, one characteristic that rarely gets discussed — but which is essential ...

When designing your own lateral flow assay (LFA), it is important to consider the critical variables that impact accuracy and reliability, including detection reagents, assay materials and ...

Lateral flow assay applications have become increasingly diverse in a post-pandemic world, and the areas of infectious disease and oncology continue to be at the forefront. In both areas, the use of ...

In this interview, Dr. Gary Pestano and Dr. Prithwish Pal discuss the advantages ddPCR offers in molecular residual disease ...

Drug resistance induced by paclitaxel and carboplatin plasmatic concentrations in lung cancer cell lines. This is an ASCO Meeting Abstract from the Markers in Cancer. This abstract does not include a ...